Home > Chemial News > Pharma News > Diabetes Drugs Market Pattern and Trend Analysis

Diabetes Drugs Market Pattern and Trend Analysis

ECHEMI 2022-05-12

The incidence of diabetes continues to increase and shows a trend of younger age. The global diabetes is getting out of control, especially in China, as a country with a large population of diabetes, diabetes has become a major public health problem. In 2019, the State Council issued the "Healthy China Action (2019-2030)", which listed diabetes prevention and control actions as one of 15 major actions. Diabetes management has been paid more and more attention by the Chinese government. The domestic diabetes drug market is about to usher in great changes.


01Market Status

China is the world's largest country with diabetes. Diabetes is a group of metabolic diseases characterized by hyperglycemia. According to the pathogenesis, diabetes can be divided into type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes mellitus and special type of diabetes mellitus. More than 90% of the overall diabetic population. According to the World Diabetes Map (10th Edition) released by the International Diabetes Federation (IDF), one out of every four diabetic patients in the world is from China. It has increased from 90 million to 140 million, an increase of 56%. The number of patients with diabetes is much higher than that of countries such as India. It is estimated that by 2045, the number of diabetic patients in my country will exceed 175 million.


Diabetes in my country is characterized by the "four lows" of awareness rate, treatment rate, control rate, and diagnosis rate. In 2018, the awareness rate of diabetes in China was 36.7%, the treatment rate was 32.9%, and the control rate was 50.1%, which was lower than the average level of middle- to high-income countries in the world during the same period. 79 years old) has not been diagnosed, the proportion is as high as 51.7%.


The status of cardiovascular safety drugs has risen significantly. There are 9 types of hypoglycemic drugs commonly used in clinical practice. Oral drugs include metformin, sulfonylurea secretagogues, glinides secretagogues, thiazolidinediones (TZDs), α-glucosidase inhibitors, and DPP-4 inhibitors. Drugs, SGLT-2 inhibitors, etc.; injectable drugs include GLP-1 receptor agonists and insulin. According to the Chinese Guidelines for the Prevention and Treatment of Diabetes (2020 Edition), metformin is the cornerstone drug for the treatment of diabetes, and combination therapy has become an important treatment method, especially for drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors that have cardiovascular benefits drug status has improved.


02Market Pattern

China's diabetes drug market space is broad. In recent years, the scale of my country's diabetes drug market has increased year by year, from 47 billion yuan in 2016 to 65.4 billion yuan in 2019, with an average increase of 11.6%. In 2020, China's diabetes drug market has slightly declined to 63.2 billion yuan, a year-on-year decrease of 3.36%. However, driven by multiple factors such as the continuous growth of diabetes patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, the diabetes market size will continue to grow in the future.


The market structure of diabetes drugs in my country is quite different from that in the world. In 2020, the first category of the domestic diabetes drug market is insulin and its analogs, accounting for 45.1%, followed by traditional oral diabetes drugs such as biguanides and α-glucosidase inhibitors, accounting for 13.2% and 12.1% respectively. %, and the sum of the three categories exceeds 70%. Compared with foreign DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptor agonists, three new types of drugs occupy half of the market, the domestic market is still in its infancy due to its late entry into the market, and the overall penetration rate is low. , the market potential is great.



Insulin centralized procurement and superimposed new drug patents have expired one after another, and domestic substitution has accelerated. In 2021, the country will officially start centralized procurement of insulin. The domestic insulin “big three” Gan & Lee Pharmaceutical, Tonghua Dongbao and United Laboratories have won bids for a number of products. The domestic market share has increased, especially the foreign-led third-generation insulin is expected to be seized through centralized procurement. more market share. At the same time, with the expiry of the patents of global hot-selling hypoglycemic drugs such as DPP-4 inhibitors and SGLT-2 inhibitors, a large number of domestic generic drug products have been launched on the market, which is about to usher in the harvest period, and domestic substitution is accelerated.


Multiple advantages have been recognized, and new drugs such as GLP-1 will seize the market. Studies have shown that SGLT-2 inhibitors and GLP-1 receptor agonists do not significantly increase the risk of hypoglycemia, can reduce body weight, and have a significant effect on reducing the risk of major cardiovascular events. As one of the standard treatments for type 2 diabetes, the market penetration rate will increase significantly. In addition, GLP-1 long-acting preparations are favored due to their better efficacy and compliance. For example, the sales of dulaglutide in 2020 exceeded US$5.3 billion, ranking among the top 1 hypoglycemic drugs in the world. In the future, long-acting preparations will be To further seize the market share of short-acting preparations.


Combination medication has become an important treatment method, and compound hypoglycemic drugs will usher in rapid growth. Judging from the national diabetes treatment guidelines, metformin combined with various hypoglycemic drugs for dual or even triple therapy is not only conducive to rapid increase in blood sugar reduction, but also beneficial to the prevention and treatment of various complications of diabetes, and has become an important means of treating diabetes. In recent years, foreign pharmaceutical companies have successively launched various compound hypoglycemic drugs. On the one hand, they improve the efficacy through complementary mechanisms, and on the other hand extend the product life cycle. For example, Merck’s blockbuster compound hypoglycemic drug sitagliptin and metformin will have global sales of nearly 2 billion in 2020. In US dollars, in the first half of 2021, the terminal sales of Chinese public medical institutions have exceeded 900 million yuan, and the sales growth rate of terminal sales in public hospitals in key cities is as high as 107.42%. In the future, compound hypoglycemic drugs will maintain a high growth trend.


The generic drug market is extremely competitive, and domestic innovative drug research and development has ushered in an upsurge. Under the policy of normalized procurement with volume and the consistency evaluation policy of generic drugs, the domestic diabetes generic drug market has become fiercely competitive. Popular varieties such as sitagliptin and acarbose have been approved for listing by more than ten companies, forcing domestic companies to enter the market. From generic drugs to Fast-follow and First-in-class, in addition to the three domestic innovative diabetes drugs that have been listed, benaglutide injection, polyethylene glycol loxenatide injection, and sitaglita sodium Outside the film, domestic pharmaceutical companies have accelerated the research and development, and many world-leading innovative drugs have entered the clinic, such as the world's only ultra-long-acting antibody drug independently developed by Hongyun Huaning that is administered once every two weeks and directly acts on the GLP-1 receptor. Already in clinical phase III, it is expected to become a new generation of ultra-long-acting hypoglycemic and weight-loss therapeutic drugs; Doyle Bio's world's first long-acting three-target agonist targeting GLP-1 receptor, GCG receptor and FGFR1c/Klothoβ DR10624 has been approved for clinical use abroad, making it the world’s first drug of its kind to enter clinical development; Hua Medicine’s self-developed dozagliatin is the world’s first glucokinase activator (GKA) to submit a new drug marketing application. It is a diabetes treatment drug, and is expected to become the world's first innovative drug to be marketed in China. The domestic enterprises have strong innovation strength.

Share to:
Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Send Message